Avoro Capital Advisors LLC Cuts Position in Vera Therapeutics, Inc. $VERA

Posted by Francis Steltz on Jun 17th, 2026

Avoro Capital Advisors LLC cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 5.2% during the fourth quarter, HoldingsChannel reports. The fund owned 5,888,888 shares of the company’s stock after selling 321,112 shares during the quarter. Vera Therapeutics comprises about 2.9% of Avoro Capital Advisors LLC’s holdings, making the stock its 13th largest position. Avoro Capital Advisors LLC owned 0.08% of Vera Therapeutics worth $298,213,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. ExodusPoint Capital Management LP acquired a new stake in shares of Vera Therapeutics in the 4th quarter worth $3,684,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Vera Therapeutics in the 4th quarter worth $71,000. Mariner LLC acquired a new stake in shares of Vera Therapeutics in the 4th quarter worth $394,000. Nicholas Investment Partners LP acquired a new stake in shares of Vera Therapeutics in the 4th quarter worth $7,333,000. Finally, First Turn Management LLC boosted its position in shares of Vera Therapeutics by 69.7% in the 4th quarter. First Turn Management LLC now owns 601,774 shares of the company’s stock worth $30,474,000 after purchasing an additional 247,245 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 1.7%

Vera Therapeutics stock opened at $33.67 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The business’s 50-day simple moving average is $36.74 and its two-hundred day simple moving average is $41.50. The company has a market cap of $2.42 billion, a PE ratio of -6.08 and a beta of 0.93. Vera Therapeutics, Inc. has a fifty-two week low of $19.07 and a fifty-two week high of $56.05.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter last year, the firm posted ($0.81) earnings per share. Equities analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on VERA shares. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a research report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Evercore set a $91.00 price objective on Vera Therapeutics in a research report on Friday, May 15th. Finally, HC Wainwright raised their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $78.00.

Read Our Latest Analysis on Vera Therapeutics

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer owned 216,744 shares in the company, valued at approximately $7,963,174.56. The trade was a 7.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Profile

(Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.